Leading Australian Research Institute Purchases HoloMonitor

June 13, 2017
Language flag

A first HoloMonitor was recently deployed at QIMR Berghofer Medical Research Institute in Brisbane Australia. With the purchase, the institute upgrades its quantitative time-lapse cytometry capacity to also include instrumentation for measuring the behavior of individual cells in a cell population, without requiring the cells to be labeled with toxic chemicals or through genetic manipulation. The customer list price of the delivered HoloMonitor system amounts to €37 500.

HoloMonitor in operation at QIMR Berghofer

“Label-free cytometers based on conventional microscopy, marketed by Essen BioScience and others, are limited to measuring the bottom area covered by a cell population. This installation is special in that HoloMonitor expands and refines QIMR Berghofer’s current time-lapse capabilities to include label-free cell population analysis on an individual cell level — a new capability that medical science just has begun to explore”, said Peter Egelberg, CEO and founder of PHI.

QIMR Berghofer is home to more than 900* scientists, students and support staff. It is one of Australia’s most successful medical research institutes. The institute was established in 1945 by the Queensland Government and has a rich history of scientific discoveries and applied medical research.

*According to recent information provided by QIMR

The above information was made public pursuant to the EU Market Abuse Regulation.

Latest News

Directed issue registered at the Companies Registration Office

PHI Board of Directors’ proposal on a directed issue to Altium S.A. was resolved on the extraordinary general meeting on November 15, 2023. The directed issue has now been registered at the Swedish Companies Registration Office.

Bulletin from extraordinary general meeting in Phase Holographic Imaging PHI AB (publ) 15 november 2023

Phase Holographic Imaging PHI AB (publ) held an extraordinary general meeting on November 15, 2023. The following resolutions were passed at the meeting.
BioStock-PHI-CEO-reflects-on-the-company-momentum

BioStock: PHI’s CEO reflects on the Company’s momentum

BioStock reached out to PHI’s CEO, Patrik Eschricht, to delve into what latest developments have contributed to the heightened enthusiasm surrounding the company.
See All News